Articles published by Immunome, Inc.
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
February 08, 2023
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome Reports Third Quarter 2022 Financial Results
November 14, 2022
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome Reports Second Quarter 2022 Financial Results
August 05, 2022
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
June 09, 2022
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
May 23, 2022
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing
February 08, 2022
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19
January 10, 2022
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald
December 07, 2021
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant
December 01, 2021
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome Reports Third Quarter 2021 Financial Results
November 15, 2021
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome to Present at the Stifel Healthcare Conference
November 09, 2021
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome to Present at the Cantor Global Healthcare Conference
September 22, 2021
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 15, 2021
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing
September 07, 2021
From Immunome, Inc.
Via Business Wire
Tickers
IMNM
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.